CA2980960C - Solution phase method for preparing etelcalcetide - Google Patents
Solution phase method for preparing etelcalcetide Download PDFInfo
- Publication number
- CA2980960C CA2980960C CA2980960A CA2980960A CA2980960C CA 2980960 C CA2980960 C CA 2980960C CA 2980960 A CA2980960 A CA 2980960A CA 2980960 A CA2980960 A CA 2980960A CA 2980960 C CA2980960 C CA 2980960C
- Authority
- CA
- Canada
- Prior art keywords
- etelcalcetide
- protected
- arg
- ala
- coupling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138903P | 2015-03-26 | 2015-03-26 | |
| US62/138,903 | 2015-03-26 | ||
| PCT/US2016/024308 WO2016154580A1 (en) | 2015-03-26 | 2016-03-25 | Solution phase method for preparing etelcalcetide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2980960A1 CA2980960A1 (en) | 2016-09-29 |
| CA2980960C true CA2980960C (en) | 2024-05-28 |
Family
ID=55911037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2980960A Active CA2980960C (en) | 2015-03-26 | 2016-03-25 | Solution phase method for preparing etelcalcetide |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10858389B2 (enExample) |
| EP (1) | EP3274360B1 (enExample) |
| JP (1) | JP6783787B2 (enExample) |
| AU (1) | AU2016238233B2 (enExample) |
| CA (1) | CA2980960C (enExample) |
| ES (1) | ES2806200T3 (enExample) |
| WO (1) | WO2016154580A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10858389B2 (en) | 2015-03-26 | 2020-12-08 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
| CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN108101959B (zh) * | 2016-11-24 | 2021-07-09 | 四川科伦药物研究院有限公司 | 一种制备高纯度多肽或其类似物的方法 |
| CN106967155B (zh) * | 2017-03-17 | 2018-05-15 | 兰州凯博药业股份有限公司 | 一种多肽液相合成缩宫素的方法 |
| CN110498835B (zh) * | 2018-05-17 | 2021-06-08 | 深圳翰宇药业股份有限公司 | 一种合成etelcalcetide的方法 |
| EP3613757A1 (en) * | 2018-08-20 | 2020-02-26 | Wntresearch AB | Solution phase routes for wnt hexapeptides |
| CN109280078B (zh) * | 2018-10-30 | 2019-06-25 | 成都诺和晟泰生物科技有限公司 | 一种制备维拉卡肽的方法 |
| CN109734778A (zh) * | 2019-03-07 | 2019-05-10 | 苏州科技大学 | 一种维拉卡肽的制备方法 |
| CN112175042B (zh) * | 2019-07-03 | 2022-05-31 | 深圳翰宇药业股份有限公司 | Etelcalcetide的合成方法 |
| WO2021038431A1 (en) | 2019-08-26 | 2021-03-04 | Auro Peptides Ltd | An improved process for the preparation of etelcalcetide hydrochloride |
| CN112521450A (zh) * | 2019-09-19 | 2021-03-19 | 深圳市健翔生物制药有限公司 | 一种固液相结合制备维拉卡肽的方法 |
| CN110668984B (zh) * | 2019-12-03 | 2020-04-10 | 凯莱英医药集团(天津)股份有限公司 | 一种依特卡肽中间体及依特卡肽的合成方法 |
| CN111925415A (zh) * | 2020-08-10 | 2020-11-13 | 海南中和药业股份有限公司 | 一种维拉卡肽杂质的制备方法 |
| EP4204434A1 (en) | 2020-08-31 | 2023-07-05 | USV Private Limited | An improved process for fmoc synthesis of etelcalcetide |
| WO2026002733A1 (en) * | 2024-06-24 | 2026-01-02 | Fresenius Kabi Ipsum S.R.L. | Method for the synthesis of a peptide with amino acids having basic side-chains |
| CN120699096B (zh) * | 2025-07-07 | 2026-01-23 | 苏州天马医药集团天吉生物制药有限公司 | 一种依特卡肽的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4738683B2 (ja) * | 1999-07-19 | 2011-08-03 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 保護されたチオールを脱保護する方法 |
| WO2009152850A1 (en) | 2008-06-17 | 2009-12-23 | Solvay (Société Anonyme) | Peptide manufacturing process |
| ES2729051T3 (es) | 2009-07-29 | 2019-10-30 | Kai Pharmaceuticals Inc | Agentes terapéuticos para reducir los niveles de hormona paratiroidea |
| WO2012068187A1 (en) | 2010-11-19 | 2012-05-24 | Merck Sharp & Dohme Corp. | Poly(amide) polymers for the delivery of oligonucleotides |
| CA2916222C (en) * | 2013-06-28 | 2021-05-18 | Amgen Inc. | Stable liquid formulation of amg 416 (etelcalcetide) |
| US10858389B2 (en) | 2015-03-26 | 2020-12-08 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
-
2016
- 2016-03-25 US US15/561,009 patent/US10858389B2/en active Active
- 2016-03-25 JP JP2017550117A patent/JP6783787B2/ja active Active
- 2016-03-25 EP EP16720588.9A patent/EP3274360B1/en active Active
- 2016-03-25 ES ES16720588T patent/ES2806200T3/es active Active
- 2016-03-25 CA CA2980960A patent/CA2980960C/en active Active
- 2016-03-25 AU AU2016238233A patent/AU2016238233B2/en active Active
- 2016-03-25 WO PCT/US2016/024308 patent/WO2016154580A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2806200T3 (es) | 2021-02-16 |
| EP3274360B1 (en) | 2020-05-06 |
| US20180079777A1 (en) | 2018-03-22 |
| US10858389B2 (en) | 2020-12-08 |
| CA2980960A1 (en) | 2016-09-29 |
| AU2016238233B2 (en) | 2019-11-21 |
| WO2016154580A1 (en) | 2016-09-29 |
| JP2018512415A (ja) | 2018-05-17 |
| JP6783787B2 (ja) | 2020-11-11 |
| EP3274360A1 (en) | 2018-01-31 |
| AU2016238233A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2980960C (en) | Solution phase method for preparing etelcalcetide | |
| US20230099078A1 (en) | Method for preparing amg 416 (etelcalcetide) | |
| US6255285B1 (en) | Phenethylamine derivatives | |
| EP4269422A1 (en) | Method for producing peptide compound containing n-substituted-amino acid residue | |
| US6235876B1 (en) | Liquid phase process for the preparation of GNRH peptides | |
| JP5212371B2 (ja) | ペプチドの製造方法 | |
| JP5445456B2 (ja) | ジベンゾフルベンの除去方法 | |
| JP2000044595A (ja) | フェネチルアミン誘導体 | |
| HK40036914A (en) | Method for preparing amg 416 | |
| JP3554399B2 (ja) | ペプチド誘導体 | |
| EP4436980A1 (en) | Synthetic process for production of modified gcc receptor agonists | |
| HK1233655A1 (en) | Method for preparing amg 416 | |
| HK1233655B (en) | Method for preparing amg 416 | |
| NO177100B (no) | Peptider | |
| WO2006097693A1 (en) | Convergent solid phase peptide synthesis by reaction of two fragments bound to solid support | |
| HK1028409A (en) | Phenethylamine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| EEER | Examination request |
Effective date: 20210104 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250226 |